Open AccessDevelopment of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells
Author(s) -
June Yong Park,
Yuseon Shin,
Woong Roeck Won,
Chaemin Lim,
Jae Chang Kim,
Kioh Kang,
Patihul Husni,
Eun Seong Lee,
Yu Seok Youn,
Kyung Taek Oh
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s315619
Subject(s) - nanocarriers , urokinase receptor , nanomedicine , biodistribution , cancer research , in vivo , cancer cell , materials science , drug delivery , cancer , chemistry , plasminogen activator , medicine , nanotechnology , biology , nanoparticle , microbiology and biotechnology
An AE147 peptide-conjugated nanocarrier based on PEGylated liposomes was developed in order to target the metastatic tumors overexpressing urokinase-type plasminogen activator receptor (uPAR), which cancer progression via uPA signaling. Therefore, the AE147 peptide-conjugated nanocarrier system may hold the potential for active targeting of metastatic tumors.